• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利用真实世界数据改善中国的药物覆盖决策。

Use of real world data to improve drug coverage decisions in China.

机构信息

Chinese Evidence-based Medicine Centre, and National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China.

出版信息

BMJ. 2023 Jun 15;381:e068911. doi: 10.1136/bmj-2021-068911.

DOI:10.1136/bmj-2021-068911
PMID:37321633
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10266438/
Abstract

discuss the rationale and propose a framework for using real world evidence to support coverage decisions in Chinese setting

摘要

探讨在华使用真实世界证据支持医保覆盖决策的基本原理，并提出一个框架

相似文献

1
Use of real world data to improve drug coverage decisions in China.利用真实世界数据改善中国的药物覆盖决策。
BMJ. 2023 Jun 15;381:e068911. doi: 10.1136/bmj-2021-068911.
2
Real-world evidence for coverage decisions: opportunities and challenges.用于医保覆盖决策的真实世界证据：机遇与挑战
J Comp Eff Res. 2018 Dec;7(12):1133-1143. doi: 10.2217/cer-2018-0066. Epub 2018 Nov 9.
3
A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions.一个指导为药物覆盖范围和处方集决策优化开发和使用真实世界证据的框架。
J Comp Eff Res. 2018 Dec;7(12):1145-1152. doi: 10.2217/cer-2018-0059. Epub 2018 Nov 14.
4
What Are the Determinants of the Decision to Purchase Private Health Insurance in China?中国购买商业健康保险的决定因素有哪些？
Int J Environ Res Public Health. 2020 Jul 24;17(15):5348. doi: 10.3390/ijerph17155348.
5
Fertility treatment decision-making: the effect of insurance coverage for fertility medications.生育治疗决策：生育药物保险覆盖范围的影响。
J Obstet Gynaecol Can. 2012 Nov;34(11):1066-1072. doi: 10.1016/S1701-2163(16)35436-6.
6
Individual health insurance within the family: can subsidies promote family coverage?家庭内部的个人健康保险：补贴能否促进家庭参保？
Inquiry. 2007 Fall;44(3):303-20. doi: 10.5034/inquiryjrnl_44.3.303.
7
Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.中国将伊马替尼作为慢性髓性白血病一线治疗的医疗保险覆盖的社会影响：一项成本效益分析。
J Med Econ. 2017 Apr;20(4):371-381. doi: 10.1080/13696998.2016.1271336. Epub 2017 Jan 12.
8
Is the individual market more than a bridge market? An analysis of disenrollment decisions.个人市场是否不仅仅是一个过渡性市场？对退保决策的分析。
Inquiry. 2005;42(4):381-96. doi: 10.5034/inquiryjrnl_42.4.381.
9
The bare necessities? A realist review of necessity argumentations used in health care coverage decisions.必需品？卫生保健覆盖决策中使用的必要性论证的现实主义综述。
Health Policy. 2017 Jul;121(7):731-744. doi: 10.1016/j.healthpol.2017.04.011. Epub 2017 May 5.
10
Risks and benefits in health care: the view from economics.医疗保健中的风险与收益：经济学视角
Health Aff (Millwood). 2007 May-Jun;26(3):653-62. doi: 10.1377/hlthaff.26.3.653.

引用本文的文献

1
Evaluating the agreement between sensitivity and primary analyses in observational studies using routinely collected healthcare data: a meta-epidemiology study.使用常规收集的医疗保健数据评估观察性研究中敏感性分析与主要分析之间的一致性：一项元流行病学研究。
BMC Med. 2025 Jul 1;23(1):393. doi: 10.1186/s12916-025-04199-4.
2
Applications of Artificial Intelligence in Drug Repurposing.人工智能在药物重新定位中的应用。
Adv Sci (Weinh). 2025 Apr;12(14):e2411325. doi: 10.1002/advs.202411325. Epub 2025 Mar 6.
3
Formulation of a CITE metric for evaluating the clinical implications of medical studies and their originating hospitals in China.制定一种用于评估中国医学研究及其发起医院临床意义的CITE指标。
Health Care Sci. 2024 Aug 6;3(4):264-273. doi: 10.1002/hcs2.108. eCollection 2024 Aug.
4
Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories.抗癌药物超说明书用药的前沿观点：分类更新与类别探索
Front Pharmacol. 2024 Jun 4;15:1374549. doi: 10.3389/fphar.2024.1374549. eCollection 2024.
5
Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings.最大化真实世界数据和真实世界证据的价值，加速中国医疗保健转型：外部顾问委员会会议总结。
Pharmaceut Med. 2024 May;38(3):157-166. doi: 10.1007/s40290-024-00520-3. Epub 2024 Apr 4.

本文引用的文献

1
Effects of Motherwort Injection Versus Intramuscular Oxytocin for Preventing Postpartum Hemorrhage Among Women Who Underwent Cesarean Section.益母草注射液与肌肉注射缩宫素对剖宫产妇女预防产后出血的效果比较
Front Pharmacol. 2022 Mar 21;13:859495. doi: 10.3389/fphar.2022.859495. eCollection 2022.
2
Electronic medical record-based deep data cleaning and phenotyping improve the diagnostic validity and mortality assessment of infective endocarditis: medical big data initiative of CMUH.基于电子病历的深度数据清理与表型分析可提高感染性心内膜炎的诊断准确性及死亡率评估：中国医药大学附设医院的医学大数据计划
Biomedicine (Taipei). 2021 Sep 1;11(3):59-67. doi: 10.37796/2211-8039.1267. eCollection 2021.
3
Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy.数据提取方案：国家卫生与保健卓越研究所（NICE）对癌症疗法评估中如何使用真实世界数据。
BMJ Open. 2022 Jan 6;12(1):e055985. doi: 10.1136/bmjopen-2021-055985.
4
Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval.利用真实世界数据模拟获得美国食品和药物管理局加速批准的治疗药物的上市后确证性临床试验的可行性。
JAMA Netw Open. 2021 Nov 1;4(11):e2133667. doi: 10.1001/jamanetworkopen.2021.33667.
5
Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.吡咯替尼为基础的治疗方案在 HER2 阳性转移性乳腺癌患者中的有效性和安全性：一项真实世界的回顾性研究。
Cancer Med. 2021 Dec;10(23):8352-8364. doi: 10.1002/cam4.4335. Epub 2021 Oct 21.
6
Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China.乐伐替尼单药治疗及基于乐伐替尼的联合治疗对不可切除肝细胞癌患者的疗效和安全性：一项在中国开展的回顾性、真实世界研究
Cancer Cell Int. 2021 Sep 18;21(1):503. doi: 10.1186/s12935-021-02200-7.
7
Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China.维得利珠单抗治疗中国中重度克罗恩病的成本效果分析。
Adv Ther. 2021 Aug;38(8):4233-4245. doi: 10.1007/s12325-021-01806-7. Epub 2021 Jun 5.
8
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.尼拉帕利治疗卵巢癌的疗效和安全性：来自中国的单中心观察性研究。
J Ovarian Res. 2021 May 17;14(1):68. doi: 10.1186/s13048-021-00803-2.
9
Estimated annual prevalence, medical service utilization and direct costs of lung cancer in urban China.中国城市肺癌的年患病率、医疗服务利用情况及直接医疗费用估计。
Cancer Med. 2021 Apr;10(8):2914-2923. doi: 10.1002/cam4.3845. Epub 2021 Mar 21.
10
Data Resource Profile: Xiamen registry of pregnant women and offspring (REPRESENT): a population-based, long-term follow-up database linking four major healthcare data platforms.数据资源简介：厦门孕妇与子代登记系统（REPRESENT）：一个基于人群的、将四个主要医疗数据平台相链接的长期随访数据库。
Int J Epidemiol. 2021 Mar 3;50(1):27-28. doi: 10.1093/ije/dyaa161.